Go Pro
→ It’s not about Greenland (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
$87.47
-2.2%		$82.33
$19.82
▼
$95.49
$12.32B1.272.36 million shs896,824 shs
LABD
Direxion Daily S&P Biotech Bear 3x Shares
$6.56
+10.6%		$8.66
$5.91
▼
$60.80
$49.59M-2.437.11 million shs21.65 million shs
Direxion Daily S&P Biotech Bull 3x Shares stock logo
LABU
Direxion Daily S&P Biotech Bull 3x Shares
$304.91
-10.7%		$260.45
$66.00
▼
$341.93
$661.66M2.44584,807 shs634,531 shs
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$519.09
-3.9%		$522.79
$392.96
▼
$615.00
$11.99B-1.01352,486 shs264,369 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
+1.72%+2.48%+24.79%+18.36%+350.20%
LABD
Direxion Daily S&P Biotech Bear 3x Shares
-17.64%-18.54%-32.00%-57.46%-90.05%
Direxion Daily S&P Biotech Bull 3x Shares stock logo
LABU
Direxion Daily S&P Biotech Bull 3x Shares
+17.78%+19.11%+37.11%+90.14%+407.65%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
+3.01%+0.74%+0.83%+5.17%+42.32%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
$87.47
-2.2%		$82.33
$19.82
▼
$95.49
$12.32B1.272.36 million shs896,824 shs
LABD
Direxion Daily S&P Biotech Bear 3x Shares
$6.56
+10.6%		$8.66
$5.91
▼
$60.80
$49.59M-2.437.11 million shs21.65 million shs
Direxion Daily S&P Biotech Bull 3x Shares stock logo
LABU
Direxion Daily S&P Biotech Bull 3x Shares
$304.91
-10.7%		$260.45
$66.00
▼
$341.93
$661.66M2.44584,807 shs634,531 shs
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$519.09
-3.9%		$522.79
$392.96
▼
$615.00
$11.99B-1.01352,486 shs264,369 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
+1.72%+2.48%+24.79%+18.36%+350.20%
LABD
Direxion Daily S&P Biotech Bear 3x Shares
-17.64%-18.54%-32.00%-57.46%-90.05%
Direxion Daily S&P Biotech Bull 3x Shares stock logo
LABU
Direxion Daily S&P Biotech Bull 3x Shares
+17.78%+19.11%+37.11%+90.14%+407.65%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
+3.01%+0.74%+0.83%+5.17%+42.32%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
2.62
Moderate Buy$97.3311.28% Upside
LABD
Direxion Daily S&P Biotech Bear 3x Shares
0.00
N/AN/AN/A
Direxion Daily S&P Biotech Bull 3x Shares stock logo
LABU
Direxion Daily S&P Biotech Bull 3x Shares
2.78
Moderate Buy$304.91N/A
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
2.78
Moderate Buy$689.9332.91% Upside

Current Analyst Ratings Breakdown

Latest LABU, MDGL, ARWR, and LABD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/17/2026
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
8/6/2026
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$115.00 ➝ $120.00
8/4/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Wolfe Research logo
Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradePeer Perform ➝ Outperform$605.00
8/3/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$964.00 ➝ $962.00
7/31/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
7/31/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
7/31/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$964.00 ➝ $962.00
7/30/2026
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
B. Riley Financial, Inc. logo
B. Riley Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$101.00 ➝ $123.00
7/29/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$578.00 ➝ $587.00
7/27/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$685.00
7/27/2026
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$100.00 ➝ $115.00
(Data available from 8/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
$829.45M14.85$0.12 per share736.18$3.31 per share26.43
LABD
Direxion Daily S&P Biotech Bear 3x Shares
N/AN/AN/AN/AN/AN/A
Direxion Daily S&P Biotech Bull 3x Shares stock logo
LABU
Direxion Daily S&P Biotech Bull 3x Shares
N/AN/AN/AN/AN/AN/A
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$958.40M12.51N/AN/A$22.67 per share22.90
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
-$1.63M-$2.25N/AN/AN/A-47.79%-60.06%-17.37%N/A
LABD
Direxion Daily S&P Biotech Bear 3x Shares
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Direxion Daily S&P Biotech Bull 3x Shares stock logo
LABU
Direxion Daily S&P Biotech Bull 3x Shares
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$288.28M-$12.89N/A93.53N/A-25.32%-56.65%-25.53%11/3/2026 (Estimated)

Latest LABU, MDGL, ARWR, and LABD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/4/2026Q3 2026
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
-$1.23-$1.36-$0.13-$1.36$44.17 million$75.25 million
7/30/2026Q2 2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$2.68-$1.99+$0.69-$1.99$352.13 million$364.25 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
N/AN/AN/AN/AN/A
LABD
Direxion Daily S&P Biotech Bear 3x Shares
$0.649.76%N/AN/AN/A
Direxion Daily S&P Biotech Bull 3x Shares stock logo
LABU
Direxion Daily S&P Biotech Bull 3x Shares
$1.010.33%N/AN/AN/A
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
1.77
5.90
5.90
LABD
Direxion Daily S&P Biotech Bear 3x Shares
N/AN/AN/A
Direxion Daily S&P Biotech Bull 3x Shares stock logo
LABU
Direxion Daily S&P Biotech Bull 3x Shares
N/AN/AN/A
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
0.65
3.20
2.94

Institutional Ownership

CompanyInstitutional Ownership
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
62.61%
LABD
Direxion Daily S&P Biotech Bear 3x Shares
N/A
Direxion Daily S&P Biotech Bull 3x Shares stock logo
LABU
Direxion Daily S&P Biotech Bull 3x Shares
N/A
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
98.50%

Insider Ownership

CompanyInsider Ownership
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
3.60%
LABD
Direxion Daily S&P Biotech Bear 3x Shares
N/A
Direxion Daily S&P Biotech Bull 3x Shares stock logo
LABU
Direxion Daily S&P Biotech Bull 3x Shares
N/A
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
17.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
400140.86 million135.79 millionOptionable
LABD
Direxion Daily S&P Biotech Bear 3x Shares
N/A7.56 millionN/ANot Optionable
Direxion Daily S&P Biotech Bull 3x Shares stock logo
LABU
Direxion Daily S&P Biotech Bull 3x Shares
N/A2.17 millionN/ANot Optionable
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
9023.10 million19.04 millionOptionable

Recent News About These Companies

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
 |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/20/3348794/0/en/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5635-c-4.html
2,410 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Acquired by State of Wyoming
August 16, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-2410-shares-in-madrigal-pharmaceuticals-inc-mdgl-acquired-by-state-of-wyoming-2026-08-16/
Madrigal’s Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expands
August 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/madrigals-rezdiffra-hits-13b-run-rate-as-mash-pipeline-expands-2026-08-15/
John Paulson's Top Q2 2026 Move: Exiting Agnico Eagle Mines Ltd at a -5.11% Portfolio Impact
August 15, 2026  |  gurufocus.comhttps://www.gurufocus.com/news/9036237/john-paulsons-top-q2-2026-move-exiting-agnico-eagle-mines-ltd-at-a-511-portfolio-impact
Madrigal Extends Resmetirom Into Pediatric MASH, Boosting Long-Term Upside for MDGL
August 13, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/madrigal-extends-resmetirom-into-pediatric-mash-boosting-long-term-upside-for-mdgl?utm_source=marketbeat.com&utm_medium=referral
Dimensional Fund Advisors LP Has $4.46 Million Stock Holdings in Madrigal Pharmaceuticals, Inc. $MDGL
August 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-dimensional-fund-advisors-lp-has-446-million-stock-holdings-in-madrigal-pharmaceuticals-inc-mdgl-2026-08-13/
Madrigal Appoints John C. Reed, M.D.
August 12, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/12/3343607/0/en/madrigal-appoints-john-c-reed-m-d-ph-d-to-its-board-of-directors.html
Madrigal Pharmaceuticals, Inc. $MDGL Shares Bought by Royal Bank of Canada
August 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-madrigal-pharmaceuticals-inc-mdgl-shares-bought-by-royal-bank-of-canada-2026-08-12/
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript
August 11, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4934870-madrigal-pharmaceuticals-inc-mdgl-presents-at-canaccord-genuitys-46th-annual-growth
Bank of America Corp DE Sells 226,498 Shares of Madrigal Pharmaceuticals, Inc. $MDGL
August 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-sells-226498-shares-of-madrigal-pharmaceuticals-inc-mdgl-2026-08-08/
Assenagon Asset Management S.A. Buys 108,181 Shares of Madrigal Pharmaceuticals, Inc. $MDGL
August 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-assenagon-asset-management-sa-buys-108181-shares-of-madrigal-pharmaceuticals-inc-mdgl-2026-08-08/
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Average Rating of "Moderate Buy" from Analysts
August 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/madrigal-pharmaceuticals-inc-nasdaqmdgl-receives-average-rating-of-moderate-buy-from-analysts-2026-08-06/
Madrigal Pharmaceuticals: Semaglutide Launch No Issue, Wise Pipeline Approach
August 5, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4930531-madrigal-pharmaceuticals-semaglutide-launch-no-issue-wise-pipeline-approach
California State Teachers Retirement System Buys 3,039 Shares of Madrigal Pharmaceuticals, Inc. $MDGL
August 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-california-state-teachers-retirement-system-buys-3039-shares-of-madrigal-pharmaceuticals-inc-mdgl-2026-08-05/
HC Wainwright Analysts Increase Earnings Estimates for MDGL
August 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/hc-wainwright-analysts-increase-earnings-estimates-for-mdgl-2026-08-04/
Madrigal Pharmaceuticals (NASDAQ:MDGL) Upgraded to Outperform at Wolfe Research
August 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/madrigal-pharmaceuticals-nasdaqmdgl-upgraded-to-outperform-at-wolfe-research-2026-08-04/
Madrigal Pharmaceuticals (MDGL) Gets a Buy from Truist Financial
August 2, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/MDGL/pressreleases/3593345/madrigal-pharmaceuticals-mdgl-gets-a-buy-from-truist-financial/
Principal Financial Group Inc. Sells 6,022 Shares of Madrigal Pharmaceuticals, Inc. $MDGL
August 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-principal-financial-group-inc-sells-6022-shares-of-madrigal-pharmaceuticals-inc-mdgl-2026-08-01/
Groupama Asset Managment Buys 4,618 Shares of Madrigal Pharmaceuticals, Inc. $MDGL
August 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-groupama-asset-managment-buys-4618-shares-of-madrigal-pharmaceuticals-inc-mdgl-2026-08-01/
Canaccord Genuity Remains a Buy on Madrigal Pharmaceuticals (MDGL)
July 31, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/MDGL-Q/pressreleases/3547851/canaccord-genuity-remains-a-buy-on-madrigal-pharmaceuticals-mdgl/
Madrigal: I Can't Bet Against A Company Performing This Well (Upgrade)
July 31, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4928689-madrigal-i-cant-bet-against-a-company-performing-this-well-upgrade

New MarketBeat Followers Over Time

Media Sentiment Over Time

Arrowhead Pharmaceuticals stock logo

Arrowhead Pharmaceuticals NASDAQ:ARWR

$87.47 -1.94 (-2.17%)
Closing price 04:00 PM Eastern
Extended Trading
$86.79 -0.68 (-0.78%)
As of 04:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Direxion Daily S&P Biotech Bear 3x Shares NYSEARCA:LABD

$6.56 +0.63 (+10.62%)
As of 04:10 PM Eastern

The Direxion Daily S&P Biotech Bear 3X Shares (LABD) is an exchange-traded fund that is based on the S&P Biotechnology Select Industry index. The fund provides daily 3 times inverse exposure to the S&P Biotechnology Select Industry Index. LABD was launched on May 28, 2015 and is managed by Direxion.

Direxion Daily S&P Biotech Bull 3x Shares stock logo

Direxion Daily S&P Biotech Bull 3x Shares NYSEARCA:LABU

$304.91 -36.64 (-10.73%)
As of 04:10 PM Eastern

The Direxion Daily S&P Biotech Bull 3X Shares (LABU) is an exchange-traded fund that is based on the S&P Biotechnology Select Industry index. The fund provides daily 3 times exposure to the S&P Biotechnology Select Industry Index. LABU was launched on May 28, 2015 and is managed by Direxion.

Madrigal Pharmaceuticals stock logo

Madrigal Pharmaceuticals NASDAQ:MDGL

$519.09 -21.07 (-3.90%)
Closing price 04:00 PM Eastern
Extended Trading
$521.50 +2.41 (+0.46%)
As of 04:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas